Background
Methods
Study population and procedure
Patient evaluation
Adipose-tissue processing, isolation of SVF and injection
Flow analysis
Culture of SVF
Mesodermal lineage differentiation assays
Cell sorting
Data and statistical analysis
Patient (P) number (#) | Gender: F/M | Age | Medical reason for SVF Rx/(classification category) | Delivery method: direct (localized) injection (DI) or I.V. | Benefit index |
---|---|---|---|---|---|
P#1 | F | 65 | Knee & poliomyelitis (1) | IV + DI | 4 |
P#2 | M | 81 | Knee (1) | IV + DI | 2 |
P#3 | F | 20 | Bladder disease (2) | IV | 5 |
P#4 | M | 70 | Optic nerve ischemia (2) | IV | 2 |
P#5 | M | 84 | Cardiac dysfunction (2) | IV | N/A |
P#6 | F | 40 | Multiple sclerosis (MS) (2) | DI | 3 |
P#7 | M | 50 | Autoimmune disease (3) | IV | N/A |
P#8 | F | 69 | Hip (1) | IV + DI | 4 |
P#9 | F | 50 | Knee (1) | IV + DI | 4 |
P#10 | F | 79 | Arthritis (1) | IV + DI | 4 |
P#11 | F | 43 | Arthritis (1) | IV + DI | N/A |
P#12 | F | 56 | Arthritis; hip (1) | IV + DI | 3 |
P#13 | F | 77 | Arthritis; shoulder (1) | IV + DI | 3 |
P#14 | F | 56 | Knee (1) | IV + DI | 3 |
P#15 | M | 64 | Arthritis; knee& shoulder (1) | IV + DI | 4 |
P#16 | M | 62 | Peyronie’s (2) | DI | 3 |
P#17 | M | 79 | Degenerative joint disease; hips and knees (1) | IV + DI | 4 |
P#18 | M | 57 | Arthritis; knee (1) | IV + DI | 4 |
P#19 | F | 46 | Fibromyalgia (2) | IV + DI | N/A |
P#20 | F | 47 | Autoimmune; lupus (3) | IV + DI | 2 |
P#21 | M | 62 | Renal dysfunction (2) | IV | 1 |
P#22 | F | 37 | Optic neuritis (2) | IV | 4 |
P#23 | F | 56 | ALS (amyotrophic lateral sclerosis) (2) | IV | 1 |
P#24 | M | 91 | Stroke (2) | IV | 3 |
P#25 | M | 55 | Spinal cord injury &arthritis; shoulder (1) | IV | 4 |
P#26 | M | 79 | Arthritis; knee (1) | IV + DI | 1 |
P#27 | F | 58 | Arthritis; foot (1) | IV + DI | 2 |
P#28 | F | 82 | Wellness & memory (2) | IV | 1 |
P#29 | F | 61 | Arthritis; knee (1) | IV + DI | N/A |
P#30 | F | 45 | Arthritis; knee (1) | IV + DI | 1 |
P#31 | F | 65 | Arthritis; knee (1) | IV + DI | 1 |
P#32 | F | 63 | Gout (1) | IV | 4 |
P#33 | M | 59 | Knee (1) | IV + DI | 4 |
P#34 | F | 76 | Arthritis; hip (1) | IV + DI | 1 |
P#35 | M | 66 | Arthritis; hip (1) | IV + DI | 3 |
P#36 | F | 66 | Shoulder (1) | IV + DI | 3 |
P#37 | M | 62 | Shoulder & knee (1) | IV + DI | N/A |
P#38 | M | 56 | Renal dysfunction (2) | IV | N/A |
P#39 | F | 16 | Torn achilles tendon (1) | IV + DI | N/A |
P#40 | M | 54 | Lower motor neuron disease (2) | DI | 1 |
P#41 | M | 62 | Arthritis; hip& knee (1) | IV + DI | 3 |
P#42 | M | 68 | Knee (1) | IV + DI | 3 |
P#43 | M | 67 | Arthritis; knee & shoulder (1) | IV + DI | 1 |
P#44 | F | 66 | Lower back pain (1) | IV + DI | 2 |
Results
Effect of gender, age, clinical condition and route of injection on the clinical outcome post-SVF treatment
Characterization of cell types in SVF
Patient characteristics and their effect on SVF yield
Patient number | BMI | Total ADSCs number/cc of fat | Total HSC-progenitors number/cc of fat | Total AT-ECs number/cc of fat | Total pericyte number/cc of fat | DN ratio (%) |
---|---|---|---|---|---|---|
1 | 22.1 | 354.6E+0 | 391.0E+0 | 85.0E+0 | 8.0E+0 | 80–98 |
2 | N/A | N/A | N/A | N/A | N/A | 5–15 |
3 | 14.7 | N/A | N/A | N/A | N/A | 5–15 |
4 | 26.5 | 3.0E+3 | 1.5E+3 | 268.8E+0 | 107.5E+0 | < 2 |
5 | 23.1 | 2.0E+3 | 924.0E+0 | 37.6E+0 | 37.2E+0 | 80–98 |
6 | 20.6 | 1.5E+3 | 192.0E+0 | 391.9E+0 | 42.4E+0 | 30–70 |
7 | 25.1 | 1.2E+3 | 630.0E+0 | 425.0E+0 | 23.5E+0 | 80–98 |
8 | 22.4 | 2.3E+3 | 1.7E+3 | 189.0E+0 | 141.1E+0 | < 2 |
9 | 27.2 | 7.6E+3 | 4.8E+3 | 2.1E+3 | 38.4E+0 | < 2 |
10 | 27.6 | 3.4E+3 | 2.1E+3 | 792.0E+0 | 61.7E+0 | < 2 |
11 | 17.2 | 9.4E+3 | 2.1E+3 | 1.7E+3 | 252.0E+0 | < 2 |
12 | 23.5 | 6.1E+3 | 5.0E+3 | 2.3E+3 | 71.9E+0 | < 2 |
13 | 35.8 | 1.4E+3 | 672.0E+0 | 434.2E+0 | 40.1E+0 | < 2 |
14 | 21 | 2.8E+3 | 3.1E+3 | 351.0E+0 | 328.5E+0 | < 2 |
15 | 27.8 | 5.4E+3 | 5.0E+3 | 400.8E+0 | 521.8E+0 | < 2 |
16 | 24.3 | 3.9E+3 | 751.0E+0 | 260.6E+0 | 142.1E+0 | < 2 |
17 | 27.2 | 568.8E+0 | 456.9E+0 | 114.4E+0 | 19.6E+0 | < 2 |
18 | 35.9 | 108.0E+0 | 172.8E+0 | 21.6E+0 | 785.0E+0 | 80–98 |
19 | 25.8 | 8.6E+3 | 2.4E+3 | 63.0E+0 | 58.2E+0 | < 2 |
20 | 25.6 | 8.3E+3 | 2.5E+3 | 735.6E+0 | 40.7E+0 | 5–15 |
21 | 30.1 | 959.0E+0 | 1.1E+3 | 137.5E+0 | 523.4E+0 | 5–15 |
22 | 39.9 | 5.1E+3 | 2.1E+3 | 1.3E+3 | 218.4E+0 | < 2 |
23 | 23.4 | 8.5E+3 | 1.7E+3 | 1.7E+3 | 381.9E+0 | < 2 |
24 | 34.4 | 1.4E+3 | 826.5E+0 | 273.1E+0 | 164.2E+0 | < 2 |
25 | 24.3 | 220.2E+0 | 34.6E+0 | 3.7E+0 | 1.6E+0 | > 99 |
26 | 28.1 | 88.8E+0 | 127.2E+0 | 1.6E+0 | 25.2E+0 | 80–98 |
27 | 26.6 | 26.4E+3 | 28.0E+3 | 2.5E+3 | 5.0E+0 | < 2 |
28 | 23.4 | 679.2E+0 | 540.0E+0 | 46.7E+0 | 50.1E+0 | 5–15 |
29 | 17.9 | 524.8E+0 | 280.0E+0 | 16.0E+0 | 163.2E+0 | 80–98 |
30 | 20 | 1.6E+3 | 460.0E+0 | 390.9E+0 | 16.4E+0 | 5–15 |
31 | 21.6 | 8.5E+3 | 3.3E+3 | 2.2E+3 | 149.4E+0 | 80–98 |
32 | 20.5 | 11.6E+3 | 4.4E+3 | 1.1E+3 | 459.4E+0 | < 2 |
33 | 34.3 | 10.9E+3 | 8.4E+3 | 1.4E+3 | 96.0E+0 | 5–15 |
34 | 25.1 | 8.8E+3 | 1.9E+3 | 3.8E+3 | 176.8E+0 | > 99 |
35 | 32 | 69.1E+0 | 64.8E+0 | 5.0E+0 | 66.7E+0 | > 99 |
36 | 23.4 | 1.9E+3 | 528.0E+0 | 1.0E+3 | 64.7E+0 | < 2 |
37 | 32.7 | 15.4E+0 | 207.9E+0 | 6.2E+0 | 3.1E+0 | < 2 |
38 | 19.8 | 295.2E+0 | 28.8E+0 | 7.2E+0 | 72.0E+0 | > 99 |
39 | 24.7 | 1.9E+3 | 213.8E+0 | 427.7E+0 | 79.2E+0 | < 2 |
40 | 21 | 1.5E+3 | 487.2E+0 | 311.8E+0 | 49.7E+0 | 30–70 |
41 | 27.2 | 1.3E+3 | 440.2E+0 | 77.0E+0 | 51.7E+0 | < 2 |
42 | 29.7 | 2.2E+3 | 1.2E+3 | 229.7E+0 | 21.1E+0 | 80–98 |
43 | 22.3 | 806.3E+0 | 121.4E+0 | 25.1E+0 | 47.9E+0 | 5–15 |
44 | 19 | 642.2E+0 | 23.9E+0 | 281.7E+0 | 118.3E+0 | > 99 |
45 | N/A | 1.2E+3 | 106.0E+0 | 29.9E+0 | 9.9E+0 | 80–98 |
46 | N/A | 1.9E+3 | 3.4E+3 | 480.5E+0 | 38.6E+0 | 5–15 |
47 | N/A | 1.6E+3 | 2.3E+3 | 166.2E+0 | 241.8E+0 | 5–15 |
48 | N/A | 1.2E+3 | 1.1E+3 | 104.3E+0 | 80.9E+0 | 30–70 |
49 | N/A | 140.0E+0 | 224.2E+0 | 7.8E+0 | 40.2E+0 | < 2 |
50 | N/A | 1.5E+3 | 2.2E+3 | 168.5E+0 | 114.1E+0 | < 2 |
51 | N/A | 3.4E+3 | 3.1E+3 | 1.6E+3 | 71.1E+0 | < 2 |
52 | N/A | 1.7E+3 | 2.0E+3 | 91.1E+0 | 23.0E+0 | < 2 |
53 | N/A | 2.1E+3 | 1.2E+3 | 169.0E+0 | 88.1E+0 | 80–98 |
54 | N/A | 500.8E+0 | 117.0E+0 | 46.8E+0 | 88.9E+0 | > 99 |
55 | N/A | 221.4E+0 | 87.4E+0 | 3.4E+0 | 2.7E+0 | < 2 |
56 | N/A | 2.2E+3 | 92.9E+0 | 108.0E+0 | 10.8E+0 | > 99 |
57 | N/A | 729.0E+0 | 324.0E+0 | 32.4E+0 | 25.9E+0 | 30–70 |
58 | N/A | 506.9E+0 | 244.0E+0 | 69.7E+0 | 66.4E+0 | 80–98 |
Culture expansion of SVFs and their differentiation potency
Expanded MSC and their therapeutic potential
Patient number | Gender: F/M | Age | Medical indication | Total number of ADE-MSCs injected (× 106) | Delivery method | Benefit index |
---|---|---|---|---|---|---|
59 | M | 84 | Parkinson | 40 | IV | 3 |
60 | F | 57 | ALS | 100 | IV | 2 |
61 | F | 41 | MS | 10 | Ommaya: 4 M IV: 6 M | 2 |
62 | M | 92 | Stroke | 80 | IV | 4 |
63 | F | 55 | MS | 135 | Ommaya: 60 M IV:75 M | 2 |
64 | M | 94 | Neuropathy | 40 | IV | 5 |
65 | M | 66 | Peyronie’s | 26 | Penile injection | 4 |
66 | M | 80 | Cardiac | 10 | IV | 3 |
67 | F | 82 | Wellness/lyme disease | 30 | IV | 4 |
68 | M | 12 | Anoxic brain injury | 20 | IV | 4 |
69 | M | 74 | Parkinson | 30 | IV | 4 |
70 | M | 69 | Erectile dysfunction | 10 | Penile injection | 1 |
71 | F | 57 | ALS | 100 | IV | 2 |
The ratio of 4 subsets in adipose tissue derived SVF injected back into the patient
Patient number | Delivery method: Direct (localized) injection (DI) or I.V | Benefit index | Ratio ADSCs: HSC-progenitors: AT-ECs (based on total number of each injected fraction) | The Ratio of ADSCs to HSC-progenitors |
---|---|---|---|---|
3 | N/A | 5 | N/A | N/A |
1 | IV + DI | 4 | 4:5:1 | 0.8 |
8 | IV + DI | 4 | 12:10:1 | 1.2 |
9 | IV + DI | 4 | 4:3:1 | 1.33 |
10 | IV + DI | 4 | 4:3:1 | 1.33 |
15 | IV + DI | 4 | 14:13:1 | 1.08 |
17 | IV + DI | 4 | 5:4:1 | 1.25 |
18 | IV + DI | 4 | 5:8:1 | 0.63 |
22 | IV | 4 | 4:2:1 | 2.00 |
25 | IV | 4 | 60:9:1 | 6.67 |
32 | IV | 4 | 11:4:1 | 2.75 |
33 | IV + DI | 4 | 7:6:1 | 1.17 |
Mean ratio of ADSCs to HSC-progenitors |
1.84
| |||
6 | DI | 3 | 4:0.5:1 | 8.00 |
12 | IV + DI | 3 | 3:2:1 | 1.50 |
13 | IV + DI | 3 | 3:2:1 | 1.50 |
14 | IV + DI | 3 | 8:9:1 | 0.89 |
16 | DI | 3 | 15:3:1 | 5.00 |
24 | IV | 3 | 5:3:1 | 1.67 |
35 | IV + DI | 3 | 14:13:1 | 1.08 |
36 | IV + DI | 3 | 2:0.5:1 | 4.00 |
41 | IV + DI | 3 | 17:6:1 | 2.83 |
42 | IV + DI | 3 | 10:5:1 | 2.00 |
Mean ratio of ADSCs to HSC-progenitors |
2.85
| |||
2 | N/A | 2 | N/A | N/A |
4 | IV | 2 | 11:6:1 | 1.83 |
20 | IV + DI | 2 | 23:3:1 | 7.67 |
27 | IV + DI | 2 | 11:11:1 | 1.00 |
44 | IV + DI | 2 | 2:0.1:1 | 20.00 |
Mean ratio of ADSCs to HSC-progenitors |
7.63
| |||
21 | IV | 1 | 3:1:1 | 3.00 |
23 | IV | 1 | 5:1:1 | 5.00 |
26 | IV + DI | 1 | 56:80:1 | 0.70 |
28 | IV | 1 | 15:12:1 | 1.25 |
30 | IV + DI | 1 | 4:1:1 | 4.00 |
31 | IV + DI | 1 | 4:1:1 | 4.00 |
34 | IV + DI | 1 | 2.5:0.5:1 | 5.00 |
40 | DI | 1 | 5:1.5:1 | 3 |
43 | IV + DI | 1 | 33:5:1 | 6.7 |
Mean ratio of ADSCs to HSC-progenitors |
3.63
| |||
5 | IV | N/A | 55:25:1 | 2.20 |
7 | IV | N/A | 3:2:1 | 1.50 |
11 | IV + DI | N/A | 6:1:1 | 6.00 |
19 | IV + DI | N/A | 272:38:1 | 7.16 |
29 | IV + DI | N/A | 33:18:1 | 1.83 |
37 | IV + DI | N/A | 3:34:1 | 1.0 |
38 | IV | N/A | 41:4:1 | 10.25 |
39 | IV + DI | N/A | 5:0.5:1 | 10.00 |
Mean ratio of ADSCs to HSC-progenitors |
4.99
|